Phase 3, randomised, placebo‐controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE

Summary Leg ulcers are a debilitating complication of sickle cell disease (SCD, including sickle cell anaemia and other sickle cell disorders) and have no proven treatments. Resolution of Sickle Cell Leg Ulcers with Voxelotor (RESOLVE) was a Phase 3, randomised, double‐blind, placebo‐controlled trial evaluating voxelotor for leg ulcer resolution in participants aged ≥12 years with SCD (homozygous haemoglobin S [HbSS]/haemoglobin S β 0 ‐thalassaemia [HbSβ 0 ]) and ≥1 active cutaneous lower‐extremity ulcer. Participants from Kenya, Nigeria and Brazil were randomised 1:1 to voxelotor 1500 mg ( N = 45) or placebo ( N = 43) for 12 weeks. The primary end‐point, complete resolution of all target ulcer(s) at Week 12, was not met (achieved resolution: voxelotor 6.7% [3/45], placebo 7.0% [3/43]; two‐sided p > 0.99). After Week 12, both groups received open‐label voxelotor. During this period, dosing was paused in May 2024, when preliminary data from four voxelotor trials, including RESOLVE, showed safety signals and potential risks that required further analysis. The trial was discontinued in September 2024 when voxelotor was withdrawn from all markets globally. In final safety analyses for RESOLVE, the most common SCD‐related treatment‐emergent adverse event (TEAE) was sickle cell anaemia with crisis (randomised period: voxelotor 44.4%, placebo 25.6%; open‐label period: continuing‐voxelotor 60.5%, delayed‐voxelotor 53.5%). Eleven participants had fatal events, nine when receiving voxelotor and two after voxelotor was paused (one after ~1 week; one after ~4 months); no deaths were considered treatment‐related. In conclusion, leg ulcer resolution was similar between groups, and the voxelotor arm had a higher rate of TEAEs.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-10-15
DOI
https://doi.org/10.1111/bjh.70856
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 3, randomised, placebo‐controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE

Carolyn C. Hoppe, Adeseye Michael Akinsete, Rodolfo Delfini Cançado, Obiageli Eunice Nnodu et al.
British Journal of Haematology
Hemoglobinopathies and Related Disorders
article

Phase 3, randomised, placebo‐controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE

Carolyn C. Hoppe, Adeseye Michael Akinsete, Rodolfo Delfini Cançado, Obiageli Eunice Nnodu, Elena Tudone, Martin Madu Meremikwu, Aderson da Silva Araújo, Halima Bello‐Manga, Patrícia Santos Resende Cardoso, Ibrahim Musa Idris, Bernhards Ragama Ogutu, Jeremy W. Rupon, José Válber Lima Meneses, the ReSolve Investigators, Janet Nyawira Oyieko, Jessie Nyokabi Githanga, Mark W. Davis, Roberto Pinto, Ching‐Ray Yu, Guilherme Fonseca
article en

Abstract

Summary Leg ulcers are a debilitating complication of sickle cell disease (SCD, including sickle cell anaemia and other sickle cell disorders) and have no proven treatments. Resolution of Sickle Cell Leg Ulcers with Voxelotor (RESOLVE) was a Phase 3, randomised, double‐blind, placebo‐controlled trial evaluating voxelotor for leg ulcer resolution in participants aged ≥12 years with SCD (homozygous haemoglobin S [HbSS]/haemoglobin S β 0 ‐thalassaemia [HbSβ 0 ]) and ≥1 active cutaneous lower‐extremity ulcer. Participants from Kenya, Nigeria and Brazil were randomised 1:1 to voxelotor 1500 mg ( N = 45) or placebo ( N = 43) for 12 weeks. The primary end‐point, complete resolution of all target ulcer(s) at Week 12, was not met (achieved resolution: voxelotor 6.7% [3/45], placebo 7.0% [3/43]; two‐sided p > 0.99). After Week 12, both groups received open‐label voxelotor. During this period, dosing was paused in May 2024, when preliminary data from four voxelotor trials, including RESOLVE, showed safety signals and potential risks that required further analysis. The trial was discontinued in September 2024 when voxelotor was withdrawn from all markets globally. In final safety analyses for RESOLVE, the most common SCD‐related treatment‐emergent adverse event (TEAE) was sickle cell anaemia with crisis (randomised period: voxelotor 44.4%, placebo 25.6%; open‐label period: continuing‐voxelotor 60.5%, delayed‐voxelotor 53.5%). Eleven participants had fatal events, nine when receiving voxelotor and two after voxelotor was paused (one after ~1 week; one after ~4 months); no deaths were considered treatment‐related. In conclusion, leg ulcer resolution was similar between groups, and the voxelotor arm had a higher rate of TEAEs.

British Journal of Haematology
Universidade Federal de Minas Gerais (BR), Universidade Federal da Bahia (BR), University of Nairobi (KE), Strathmore University (KE), Pfizer (United States) (US), University of Lagos (NG), United States Army Medical Research Directorate - Africa (KE), Kenya Medical Research Institute (KE), Kaduna State University (NG), University of Calabar (NG), Hospital Samaritano de São Paulo (BR), University of Abuja Teaching Hospital (NG), Hospital das Clínicas da Universidade Federal de Minas Gerais (BR), Fundação Hemopa (BR), Pfizer (Italy) (IT), Hospital Universitário da Universidade de São Paulo (BR), University of Abuja (NG), Bayero University Kano (NG)
Pfizer
Good health and well-being
Openalex Percentile: Top 14%
Hemoglobinopathies and Related Disorders
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.